Eyepoint Pharmaceuticals Inc (EYPT) — Strategic Asset Allocation Index
Eyepoint Pharmaceuticals Inc (EYPT) has a Strategic Asset Allocation Index of 5.0% as of June 2023. Strategic assets (PP&E of $2.87 Million plus long-term investments of $-) total $2.87 Million, measured against net assets of $57.26 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Eyepoint Pharmaceuticals Inc Strategic Asset Allocation Index (2002–2022)
This chart shows how Eyepoint Pharmaceuticals Inc's Strategic Asset Allocation Index has evolved across 21 annual periods from 2002 to 2022. As of June 2023, the index stands at 5.0%, representing strategic assets of $2.87 Million against net assets of $57.26 Million USD. Explore EYPT cash generation efficiency to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Eyepoint Pharmaceuticals Inc (2002–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Eyepoint Pharmaceuticals Inc from 2002 to 2022, covering 21 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see EYPT stock market capitalisation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 1.4% | $1.36 Million | $1.36 Million | $- | $96.37 Million | ▲ +0.2 pp |
| 2021 | 1.2% | $2.25 Million | $2.25 Million | $- | $184.38 Million | ▼ -2.2 pp |
| 2020 | 3.4% | $630.00K | $630.00K | $- | $18.54 Million | ▼ -0.9 pp |
| 2019 | 4.3% | $357.00K | $357.00K | $- | $8.33 Million | ▲ +1.8 pp |
| 2018 | 2.5% | $288.00K | $288.00K | $- | $11.69 Million | ▲ +0.6 pp |
| 2017 | 1.9% | $253.00K | $253.00K | $- | $13.34 Million | ▲ +0.4 pp |
| 2016 | 1.5% | $313.00K | $313.00K | $- | $20.88 Million | ▲ +0.3 pp |
| 2015 | 1.2% | $290.00K | $290.00K | $- | $23.37 Million | ▼ -1.0 pp |
| 2014 | 2.3% | $338.00K | $338.00K | $- | $14.92 Million | ▼ -1.6 pp |
| 2013 | 3.9% | $297.00K | $297.00K | $- | $7.70 Million | ▲ +2.5 pp |
| 2012 | 1.3% | $179.00K | $179.00K | $- | $13.64 Million | ▲ +0.4 pp |
| 2011 | 0.9% | $335.00K | $335.00K | $- | $37.43 Million | ▲ +0.5 pp |
| 2010 | 0.4% | $123.00K | $123.00K | $- | $33.04 Million | ▲ +0.2 pp |
| 2009 | 0.2% | $43.00K | $43.00K | $- | $23.54 Million | ▼ -0.1 pp |
| 2008 | 0.3% | $66.00K | $66.00K | $- | $21.79 Million | ▼ -0.4 pp |
| 2007 | 0.7% | $473.00K | $473.00K | $- | $65.91 Million | ▼ -0.1 pp |
| 2006 | 0.8% | $512.00K | $512.00K | $- | $66.20 Million | ▼ -3.1 pp |
| 2005 | 3.8% | $2.33 Million | $2.33 Million | $- | $60.74 Million | ▼ -0.3 pp |
| 2004 | 4.1% | $2.49 Million | $2.49 Million | $- | $60.74 Million | ▲ +2.4 pp |
| 2003 | 1.7% | $466.00K | $466.00K | $- | $26.70 Million | ▼ -4.7 pp |
| 2002 | 6.4% | $271.00K | $271.00K | $- | $4.23 Million | — |